Landon v. Kroll Laboratory Specialists, Inc.

91 A.D.3d 79, 934 N.Y.2d 183
CourtAppellate Division of the Supreme Court of the State of New York
DecidedNovember 22, 2011
StatusPublished
Cited by26 cases

This text of 91 A.D.3d 79 (Landon v. Kroll Laboratory Specialists, Inc.) is published on Counsel Stack Legal Research, covering Appellate Division of the Supreme Court of the State of New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Landon v. Kroll Laboratory Specialists, Inc., 91 A.D.3d 79, 934 N.Y.2d 183 (N.Y. Ct. App. 2011).

Opinion

OPINION OF THE COURT

Miller, J.

In this case we are called upon to determine whether a drug testing laboratory may be held liable in tort to the subject of a drug test for negligently testing that subject’s biological specimen notwithstanding the absence of a formal contractual relationship between the drug testing laboratory and the subject of the drug test. We answer the question in the affirmative.

The complaint in this action alleged that the defendant, Kroll Laboratory Specialists, Inc., was a Louisiana corporation which held a New York State Department of Health Laboratory Permit for Comprehensive Forensic Toxicology and which was in the business of performing forensic toxicology testing to determine the presence or absence of illicit or controlled substances. The defendant entered into a contract with the Orange County Probation Department to analyze oral fluid samples provided by individuals on probation.

On January 28, 2002, the plaintiff was convicted of forgery in the second degree in Orange County. The County Court sentenced the plaintiff to a five-year term of probation. As a condition of his sentence, the plaintiff was required to submit to periodic and random drug testing at the direction of his probation officer.

The plaintiff alleged that on December 17, 2007, while still serving his probationary sentence, he was directed by his probation officer to submit an oral fluid sample for the purpose of determining whether he was complying with the terms of his probation. An oral sample was taken by the plaintiff ‘s probation officer utilizing a device known as “the Intercept DO A Oral Specimen Collection Device” which was manufactured by Orasure Technologies, Inc. (hereinafter Orasure), and which had been purchased from the defendant for such purposes. The [81]*81oral sample was sent to the defendant to determine whether it contained illicit or controlled substances.

Later that day on December 17, 2007, the plaintiff obtained an independent blood test, which revealed that the plaintiff’s blood sample was negative for illicit or controlled substances on December 17, 2007.

The complaint stated that the oral sample provided by the plaintiff was received at the defendant’s facility on December 20, 2007. Screening was performed in accordance with the defendant’s standard policy and practice utilizing a “Micro-Plate EIA,” a device also developed by Orasure. It was determined that the oral sample contained amounts of cannabinoids which exceeded the defendant’s screen test cutoff level of 1.0 ng/mL.

In a written report dated December 20, 2007, the defendant informed the Orange County Probation Department that the oral sample tested positive for marijuana. The complaint alleged that as a result of this erroneous report, the plaintiff’s probationary sentence was extended for months beyond the original term and he was compelled to make multiple court appearances to prevent his incarceration based on the erroneous test result.

The plaintiff claimed that the defendant utilized a screen test cutoff level of only 1.0 ng/mL despite the fact that Orasure, the manufacturer of the collection device and the developer of the testing method, recommended a screen test cutoff level of at least 3.0 ng/mL. Moreover, the complaint alleged that the industry-wide standard for forensic drug testing required a screen test cutoff level of 4.0 ng/mL.

In addition, the complaint alleged that the test performed by the defendant was never confirmed by use of a gas chromatography-mass spectrometry test (hereinafter a GC/MS test) or by any other method. The complaint further alleged that holders of a New York State Department of Health Laboratory Permit for Comprehensive Forensic Toxicology were required to utilize a GC/MS test before reporting a positive test result.

The defendant moved to dismiss the complaint asserting, among other things, that the plaintiff failed to state a cause of action. The Supreme Court granted that branch of the defendant’s motion and dismissed the complaint pursuant to CPLR 3211 (a) (7). We reverse the order insofar as appealed from.

“A party may move for judgment dismissing one or more causes of action asserted against [it] on the ground that. . . the [82]*82pleading fails to state a cause of action” (CPLR 3211 [a] [7]). “When assessing the adequacy of a complaint in light of a CPLR 3211 (a) (7) motion to dismiss, the court must afford the pleadings a liberal construction, accept the allegations of the complaint as true and provide plaintiff. . . ‘the benefit of every possible favorable inference’ ” (AG Capital Funding Partners, L.P. v State St. Bank & Trust Co., 5 NY3d 582, 591 [2005], quoting Leon v Martinez, 84 NY2d 83, 87 [1994]).

“Whether a plaintiff can ultimately establish its allegations is not part of the calculus in determining a motion to dismiss” (EBC I, Inc. v Goldman, Sachs & Co., 5 NY3d 11, 19 [2005]). Rather, a court must “determine only whether the facts as alleged fit within any cognizable legal theory” (Leon v Martinez, 84 NY2d at 87-88; see Sokoloff v Harriman Estates Dev. Corp., 96 NY2d 409, 414 [2001]).

The Court of Appeals has recognized that “the line separating tort and contract claims may be elusive [and] the classification . . . consequential” (Sommer v Federal Signal Corp., 79 NY2d 540, 551 [1992]; see Preferred Mut. Ins. Co. v C. Rumbalski Chimney Sweep, 46 AD3d 866, 867 [2007]). In order to gain perspective on this issue, we begin by considering the source of the respective duties imposed in tort law and contract law.

“Duty is essentially a legal term by which we express our conclusion that there can be liability” (De Angelis v Lutheran Med. Ctr., 58 NY2d 1053, 1055 [1983]). Obligations that flow exclusively from a contract must be enforced as contractual duties under a theory of contract law (see Church v Callanan Indus., 99 NY2d 104, 111 [2002]; Stiver v Good & Fair Carting & Moving, Inc., 32 AD3d 1209, 1210 [2006], affd 9 NY3d 253 [2007]; see also Prosser and Keeton, Torts § 92, at 655-656 [5th ed]). Thus “where a party is merely seeking to enforce its bargain, a tort claim will not lie” (New York Univ. v Continental Ins. Co., 87 NY2d 308, 316 [1995]; see Board of Mgrs. of the Chelsea 19 Condominium v Chelsea 19 Assoc., 73 AD3d 581, 582 [2010]; Megaris Furs v Gimbel Bros., 172 AD2d 209, 211 [1991]). Furthermore, a court enforcing a contractual obligation will ordinarily impose a contractual duty only on the promisor in favor of the promisee and any intended third-party beneficiaries (see Eaves Brooks Costume Co. v Y.B.H. Realty Corp., 76 NY2d 220, 226 [1990]).

On the other hand, “[a] tort obligation is a duty imposed by law to avoid causing injury to others” (New York Univ. v Continental Ins. Co., 87 NY2d at 316). Accordingly, “the liability [83]*83to make reparation for an injury rests not upon the consideration of any reciprocal obligation, but upon an original moral duty enjoined upon every person so to conduct himself [or herself], or exercise his [or her] own rights as not to injure another” (Rich v New York Cent. & Hudson Riv. R.R. Co., 87 NY 382, 398 [1882]; see New York Univ. v Continental Ins. Co., 87 NY2d at 316; Havas v Victory Paper Stock Co., 49 NY2d 381, 386 [1980]; see also Heaven v Pender, 11 QBD 503, 509 [1883, Brett, M.R.]).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

D & A Grandview LLC v. 60 Davidson LLC
2025 NY Slip Op 50221(U) (New York Supreme Court, Kings County, 2025)
Geotech Enters., Inc. v. 181 Edgewater, LLC
2021 NY Slip Op 01394 (Appellate Division of the Supreme Court of New York, 2021)
Topiel v. Caremount Med., P.C.
Appellate Terms of the Supreme Court of New York, 2020
Aponte v. Estate of Rene Aponte
2019 NY Slip Op 3750 (Appellate Division of the Supreme Court of New York, 2019)
Bracken v. MH Pillars Inc.
290 F. Supp. 3d 258 (S.D. Illinois, 2017)
Travelsavers Enterprises, Inc. v. Analog Analytics, Inc.
2017 NY Slip Op 3035 (Appellate Division of the Supreme Court of New York, 2017)
Abrams v. Bute
138 A.D.3d 179 (Appellate Division of the Supreme Court of New York, 2016)
Bennett v. State Farm Fire & Casualty Co.
137 A.D.3d 727 (Appellate Division of the Supreme Court of New York, 2016)
B.F. v. Reproductive Medicine Associates of New York, LLP
136 A.D.3d 73 (Appellate Division of the Supreme Court of New York, 2015)
Braverman v. Bendiner & Schlesinger, Inc.
121 A.D.3d 353 (Appellate Division of the Supreme Court of New York, 2014)
Horn v. Toback
44 Misc. 3d 42 (Appellate Terms of the Supreme Court of New York, 2014)
Fuller v. Collins
114 A.D.3d 827 (Appellate Division of the Supreme Court of New York, 2014)
In re Facebook, Inc., IPO Securities & Derivative Litigation
986 F. Supp. 2d 428 (S.D. New York, 2013)
Encore Lake Grove Homeowners Ass'n v. Cashin Associates
111 A.D.3d 881 (Appellate Division of the Supreme Court of New York, 2013)
Landon v. Kroll Laboratory Specialists, Inc.
999 N.E.2d 1121 (New York Court of Appeals, 2013)
Pasternack v. Laboratory Corp. of America
892 F. Supp. 2d 540 (S.D. New York, 2012)
Banco Multiple Santa Cruz v. Moreno
888 F. Supp. 2d 356 (E.D. New York, 2012)
Way v. City of Beacon
96 A.D.3d 829 (Appellate Division of the Supreme Court of New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
91 A.D.3d 79, 934 N.Y.2d 183, Counsel Stack Legal Research, https://law.counselstack.com/opinion/landon-v-kroll-laboratory-specialists-inc-nyappdiv-2011.